Lynn Seely - Feb 9, 2024 Form 4 Insider Report for Lyell Immunopharma, Inc. (LYEL)

Role
President and CEO, Director
Signature
/s/ Charles Newton, as Attorney-in-Fact
Stock symbol
LYEL
Transactions as of
Feb 9, 2024
Transactions value $
$0
Form type
4
Date filed
2/13/2024, 08:17 PM
Previous filing
Nov 20, 2023
Next filing
Jun 14, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction LYEL Common Stock Award $0 +200K $0.00 200K Feb 9, 2024 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The reported transaction involved the Reporting Person's receipt of a grant of performance-based restricted stock units, subject to vesting upon the achievement of specified performance criteria. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.